Cefadroxil is a broad-spectrum, first-generation cephalosporin antibiotic used primarily for the treatment of mild to moderate bacterial infections. It is a semisynthetic, beta-lactam antibiotic structurally and pharmacologically similar to cephalexin and cefradine, but with a distinct pharmacokinetic profile that allows for once- or twice-daily dosing. This report provides a detailed examination of cefadroxil, covering its mechanism of action, antimicrobial spectrum, pharmacokinetics, clinical indications, adverse effects, contraindications, and resistance patterns.
Mechanism of Action
Like all beta-lactam antibiotics, cefadroxil exerts its bactericidal effect by inhibiting bacterial cell wall synthesis. It binds to penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, interfering with the transpeptidation step of peptidoglycan cross-linking. This disruption weakens the cell wall, leading to osmotic instability and cell lysis. Cefadroxil is most effective against actively dividing bacteria.
Antimicrobial Spectrum
Cefadroxil is primarily active against Gram-positive bacteria, including Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pyogenes (Group A beta-hemolytic streptococci), Streptococcus pneumoniae, and Streptococcus agalactiae (Group B streptococci). It also has activity against some Gram-negative organisms such as Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Haemophilus influenzae (though with variable susceptibility). It is not effective against methicillin-resistant Staphylococcus aureus (MRSA), enterococci, Pseudomonas aeruginosa, or anaerobes like Bacteroides fragilis. Compared to later-generation cephalosporins, its Gram-negative coverage is limited.
Pharmacokinetics
Cefadroxil is administered orally and is well absorbed from the gastrointestinal tract, with a bioavailability exceeding 90%. Its absorption is not significantly affected by food. Peak serum concentrations are achieved 1–2 hours after dosing. The drug has a longer elimination half-life (approximately 1.5–2 hours) compared to other first-generation cephalosporins, which allows for twice-daily or even once-daily dosing for some infections. It is widely distributed into body tissues and fluids, including the pleural, synovial, and peritoneal cavities, as well as bone, bile, and soft tissues. However, it does not cross the blood-brain barrier in sufficient concentrations to treat meningitis. Cefadroxil is primarily excreted unchanged by the kidneys via glomerular filtration and tubular secretion, requiring dose adjustment in patients with renal impairment.
Clinical Indications
Cefadroxil is approved for the treatment of a variety of infections caused by susceptible organisms:
- Upper respiratory tract infections: Pharyngitis, tonsillitis, and sinusitis (especially due to S. pyogenes).
- Urinary tract infections (UTIs): Uncomplicated cystitis and pyelonephritis caused by E. coli, K. pneumoniae, or P. mirabilis.
- Skin and soft tissue infections: Impetigo, cellulitis, furunculosis, and wound infections caused by staphylococci and streptococci.
- Bone and joint infections (as part of combination therapy): Osteomyelitis due to susceptible Gram-positive cocci.
- Prophylaxis: Sometimes used to prevent endocarditis in at-risk patients undergoing dental or surgical procedures, though guidelines have shifted toward other agents.
Dosage and Administration
Dosage varies by age, renal function, and infection severity. For adults with normal renal function, typical doses for mild to moderate infections range from 500 (http://Merceriavaccarella.it) mg to 1 gram twice daily. For streptococcal pharyngitis, a once-daily dose of 1 gram for 10 days is common. Pediatric doses are weight-based (usually 30 mg/kg/day divided into one or two doses). In renal impairment, both the dose and frequency are reduced according to creatinine clearance.
Adverse Effects
Cefadroxil is generally well tolerated, with adverse effects occurring in a minority of patients. Common side effects include gastrointestinal disturbances such as diarrhea, nausea, vomiting, and abdominal discomfort. Hypersensitivity reactions, ranging from mild skin rashes to urticaria and pruritus, occur in about 1–3% of patients. Serious reactions such as anaphylaxis, Stevens-Johnson syndrome, or drug-induced hypersensitivity are rare. Other less common effects include headache, dizziness, transient elevations in liver enzymes, and eosinophilia. Pseudomembranous colitis due to Clostridioides difficile overgrowth can occur with any antibiotic, including cefadroxil. Long-term use may lead to superinfection with resistant organisms.
Contraindications and Precautions
Cefadroxil is contraindicated in patients with a known hypersensitivity to cephalosporins or any component of the formulation. Cross-allergenicity with penicillins occurs in about 5–10% of patients, so caution is advised in those with a history of penicillin allergy, especially if the reaction was immediate or severe. Other precautions include use in patients with renal impairment (dose adjustment needed), gastrointestinal disease (especially colitis), and in pregnancy (FDA category B – presumed safe based on animal studies, but limited human data). It should be used with caution in breast-feeding mothers as it is excreted in breast milk in small amounts.
Drug Interactions
Probenecid can decrease renal tubular secretion of cefadroxil, leading to increased and prolonged serum concentrations. Concomitant use with warfarin may enhance anticoagulant effects. Use with oral contraceptives may theoretically reduce efficacy (though not clinically significant). No major interactions with food or antacids have been reported.
Resistance
Bacterial resistance to cefadroxil can occur through several mechanisms: production of beta-lactamases (especially by Gram-negative bacilli), alteration of PBPs (as in MRSA), or decreased permeability of the bacterial outer membrane. The prevalence of resistance among common pathogens varies geographically. Community-acquired methicillin-resistant S. aureus (CA-MRSA) is often resistant to first-generation cephalosporins, limiting their utility for skin infections in areas with high CA-MRSA incidence. Extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales are also resistant. Therefore, cefadroxil is best reserved for infections likely caused by susceptible organisms, guided by local susceptibility patterns and culture results when possible.
Comparison with Other Cephalosporins
Among first-generation cephalosporins, cefadroxil’s main advantage is its extended half-life, permitting less frequent dosing, which can improve patient compliance. Its spectrum is essentially the same as cephalexin, though some strains may have slightly different minimum inhibitory concentrations. It is generally more expensive than generic cephalexin in some markets, but the convenience factor often justifies its use. For infections requiring broader Gram-negative coverage, second- or third-generation agents such as cefuroxime or ceftriaxone may be preferred.
Conclusion
Cefadroxil remains a valuable oral antibiotic for the treatment of select Gram-positive infections and uncomplicated urinary tract infections. Its favorable pharmacokinetics and good safety profile make it a convenient option for both adult and pediatric patients. However, due to increasing antimicrobial resistance, its use should be rationalized based on microbiological data and local guidelines. When prescribed appropriately, cefadroxil provides effective and reliable therapy for common community-acquired infections.
